Running Point Capital Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Running Point Capital Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,500	Closed	-$14K	–	211
2022 Q3	$14K	Hold	1,500	–	–	0.01%	191
2022 Q2	$18K	Hold	1,500	–	–	0.01%	186
2022 Q1	$20K	Buy	+1,500	New	+$21.9K	0.01%	187

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Running Point Capital Advisors's ADVM Position: Q4 2022 in Review

Running Point Capital Advisors sold out of Adverum Biotechnologies (ADVM) in Q4 2022, closing a stake of 1,500 shares — an estimated $14K sold.

Running Point Capital Advisors first reported a position in ADVM in Q1 2022 and held it in 3 quarters. The position peaked at $20K in Q1 2022. 59 funds tracked by Wall St. Rank hold ADVM as of Q4 2022.

Running Point Capital Advisors reported no remaining Adverum Biotechnologies position as of Q4 2022 after selling out during the quarter.
Running Point Capital Advisors sold 1,500 Adverum Biotechnologies shares in Q4 2022, an estimated $14K.
Running Point Capital Advisors first reported a position in Adverum Biotechnologies in Q1 2022 and held it in 3 quarters.
Running Point Capital Advisors's Adverum Biotechnologies position peaked at $20K in Q1 2022.
59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2022.

Based on Running Point Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.